• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

FDA actions in brief

Article

Sodium phosphate monobasic monohydrate/sodium phosphate dibasic anhydrous tablets (OsmoPrep, Salix) were approved by FDA for cleansing of the colon prior to colonoscopy in patients aged 18 years or older.

Sodium phosphate monobasic monohydrate/sodium phosphate dibasic anhydrous tablets (OsmoPrep, Salix) were approved by FDA for cleansing of the colon prior to colonoscopy in patients aged 18 years or older.

FDA approved omeprazole/sodium bicarbonate (Zegerid, Santarus), an immediate-release proton pump inhibitor (PPI), for the short-term treatment of active duodenal ulcers and erosive esophagitis diagnosed by endoscopy, the short-term treatment of active benign gastric ulcers, the maintenance of healing of erosive esophagitis, and for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD).

© 2024 MJH Life Sciences

All rights reserved.